Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis

Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract. In biological therapy, infliximab became the first anti-tumor necrosis factor (TNF) agent approved for IBD. Despite this success, infliximab is expensive, often ineffective, and assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaddoura, Rachid, Ghelani, Hardik, Alqutami, Fatma, Altaher, Hala, Hachim, Mahmood, Jan, Reem Kais
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057676/
https://www.ncbi.nlm.nih.gov/pubmed/36983834
http://dx.doi.org/10.3390/life13030680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057676/
https://www.ncbi.nlm.nih.gov/pubmed/36983834
http://dx.doi.org/10.3390/life13030680

Ejemplares similares